HRS-1167 tablets clinical trial approved
April 22, 2025
Source: drugdu
81
On April 20, the company announced that HRS-1167 tablets obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration and will conduct clinical trials in the near future. HRS-1167 tablets are highly selective, highly active, and orally available PARP1 small molecule inhibitors independently developed by the company with intellectual property rights. They belong to the second generation of PARP inhibitors. Compared with the first generation of PARP inhibitors, HRS-1167 has higher selectivity and stronger affinity for PARP1. HRS-1167 is currently in the early clinical development stage and has the potential to be used as a monotherapy and combination therapy to treat more patients, including tumor patients who were previously unable to use PARP inhibitors. Upon inquiry, no similar products have been approved for marketing at home and abroad. As of now, the R&D expenses of HRS-1167 tablets related projects have accumulated to approximately RMB 72.11 million.
https://finance.eastmoney.com/a/202504203382099145.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Bivalirudin for injection obtains marketing authorization from the Australian Therapeutic Goods Administration May 8, 2025
- HDM2005 for injection obtains drug clinical trial approval notice May 8, 2025
- The 10 billion-dollar ankylosing spondylitis market is undergoing a transformation May 8, 2025
- The 100 billion yuan autoimmune disease prevention market, the next outbreak point May 8, 2025
- Medical research has found that those who did not develop lung cancer despite having pneumonia all had these three dietary habits. May 8, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
